<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lineage Cell Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc</link>
<description>Latest news and press releases for Lineage Cell Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lineage-cell-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d764c751cc36e47533aaa1.webp</url>
<title>Lineage Cell Therapeutics, Inc.</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc</link>
</image>
<item>
<title>Lineage Announces Formation of Scientific Advisory Board</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-announces-formation-of-scientific-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-announces-formation-of-scientific-advisory-board</guid>
<pubDate>Mon, 13 Apr 2026 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., April 13, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced the formation of a Scientific Advisory Board (SAB) to provide strategic counsel and insights into the development of Lineage’s novel cell transplant pipeline, built on the Company’s proprietary cell differentiation and expansion platform, AlloSCOPE™ (</description>
</item>
<item>
<title>Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-launches-new-cell-therapy-program-in-corneal-endothelial-disease</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-launches-new-cell-therapy-program-in-corneal-endothelial-disease</guid>
<pubDate>Tue, 24 Mar 2026 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., March 24, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline with the launch of COR1, a new corneal endothelial cell (CEnC) therapy program, in preclinical development for the treatment of corneal endothelial disease. Corneal endothelial disease is a progressive, of</description>
</item>
<item>
<title>Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-40</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-40</guid>
<pubDate>Thu, 05 Mar 2026 21:01:00 GMT</pubDate>
<description>CARLSBAD, Calif., March 05, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today reported its fourth quarter and full year 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.</description>
</item>
<item>
<title>Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-5-2026</guid>
<pubDate>Thu, 26 Feb 2026 13:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., February 26, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its fourth quarter and full year 2025 financial and operating results on Thursday, March 5, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 5,</description>
</item>
<item>
<title>Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-takes-delivery-of-gene-edited-hypoimmune-cell-line-under-partnership-with-factor-bioscience</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-takes-delivery-of-gene-edited-hypoimmune-cell-line-under-partnership-with-factor-bioscience</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., January 06, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, today announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. ("Factor"). Generation of the line marks a successful milestone in the strategic collaboration between the two companies, un</description>
</item>
<item>
<title>Lineage Cell Therapeutics Issues Letter to Stockholders</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-issues-letter-to-stockholders</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-issues-letter-to-stockholders</guid>
<pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., January 05, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, today published a letter to shareholders highlighting the company’s achievements throughout 2025 and its corporate outlook for 2026.</description>
</item>
<item>
<title>Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 06 Nov 2025 21:01:00 GMT</pubDate>
<description>CARLSBAD, Calif., November 06, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.</description>
</item>
<item>
<title>Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-6-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-6-2025</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., October 30, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 6, 2025, at</description>
</item>
<item>
<title>Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-initiates-cell-transplant-program-in-type-1-diabetes</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-initiates-cell-transplant-program-in-type-1-diabetes</guid>
<pubDate>Mon, 08 Sep 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., September 08, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced the initiation of a new islet cell transplant program in Type 1 Diabetes (T1D). Specifically, the company aims to deploy its manufacturing capability to address the issue of large-scale production of islet cells, with the initial goal of establish</description>
</item>
<item>
<title>Lineage Cell Therapeutics to Present at September 2025 Investor Conferences</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-present-at-september-2025-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-present-at-september-2025-investor-conferences</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., September 02, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference, on September 8, 2025, at 11:30am ET and at Baird's 2025 Global Healthcare Conference,</description>
</item>
<item>
<title>Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-announces-research-collaboration-with-william-demant-invest-to-develop-resonancetm-anp1-for-hearing-loss</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-announces-research-collaboration-with-william-demant-invest-to-develop-resonancetm-anp1-for-hearing-loss</guid>
<pubDate>Tue, 26 Aug 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., August 26, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious neurological and ophthalmic conditions, today announced that it has entered into a research collaboration with and through an investment from William Demant Invest A/S (WDI). WDI is an evergreen investor and the holding company for William Demant Foundation’s investment activities – a</description>
</item>
<item>
<title>Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 12 Aug 2025 20:01:00 GMT</pubDate>
<description>CARLSBAD, Calif., August 12, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its second quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.</description>
</item>
<item>
<title>Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-report-second-quarter-2025-financial-results-and-provide-business-update-on-august-12-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-report-second-quarter-2025-financial-results-and-provide-business-update-on-august-12-2025</guid>
<pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., August 05, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its second quarter 2025 financial and operating results on Tuesday, August 12, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, August 12, 2025, at 4:30 p.m. Eastern Ti</description>
</item>
<item>
<title>Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-announces-dosing-of-first-patient-in-new-clinical-study-of-opc1-for-subacute-and-chronic-spinal-cord-injury</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-announces-dosing-of-first-patient-in-new-clinical-study-of-opc1-for-subacute-and-chronic-spinal-cord-injury</guid>
<pubDate>Mon, 04 Aug 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., August 04, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, announced today that the first-ever chronic spinal cord injury patient has been treated in the Company’s DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study at UC San Die</description>
</item>
<item>
<title>OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/opregenr-rg6501-36-month-visual-acuity-results-featured-at-clinical-trials-at-the-summit-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/opregenr-rg6501-36-month-visual-acuity-results-featured-at-clinical-trials-at-the-summit-2025</guid>
<pubDate>Mon, 23 Jun 2025 11:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., June 23, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD</description>
</item>
<item>
<title>Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-announces-updates-to-the-3rd-annual-spinal-cord-injury-investor-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-announces-updates-to-the-3rd-annual-spinal-cord-injury-investor-symposium</guid>
<pubDate>Thu, 05 Jun 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., June 05, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025.</description>
</item>
<item>
<title>Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-to-present-at-3rd-annual-hc-wainwright-bioconnect-investor-conference-at-nasdaq-nyc</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-to-present-at-3rd-annual-hc-wainwright-bioconnect-investor-conference-at-nasdaq-nyc</guid>
<pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., May 14, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd Annual</description>
</item>
<item>
<title>Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 13 May 2025 20:01:00 GMT</pubDate>
<description>CARLSBAD, Calif., May 13, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its first quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.</description>
</item>
<item>
<title>RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/rg6501-opregenr-phase-12a-clinical-study-36-month-results-to-be-featured-at-clinical-trials-at-the-summit-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/rg6501-opregenr-phase-12a-clinical-study-36-month-results-to-be-featured-at-clinical-trials-at-the-summit-2025</guid>
<pubDate>Mon, 12 May 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., May 12, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at Clinical Trials at</description>
</item>
<item>
<title>Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025</title>
<link>https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update-on-may-13-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lineage-cell-therapeutics-inc/news/lineage-cell-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business-update-on-may-13-2025</guid>
<pubDate>Thu, 01 May 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., May 01, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.</description>
</item>
</channel>
</rss>